PortalPublikationenThe cellular ratio of immune tolerance (immunoCRIT) is a def...

The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns

Standard

The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. / Türbachova, Ivana; Schwachula, Tim; Vasconcelos, Ines; Mustea, Alexander; Baldinger, Tina; Jones, Katherine A; Bujard, Hermann; Olek, Alexander; Olek, Klaus; Gellhaus, Katharina; Braicu, Ioana; Könsgen, Dominique; Fryer, Christy; Ravot, Elisabetta; Hellwag, Alexander; Westerfeld, Nicole; Gruss, Oliver J; Meissner, Markus; Hasan, Mazahir T; Weber, Michael; Hoffmüller, Ulrich; Zimmermann, Sven; Loddenkemper, Christoph; Mahner, Sven; Babel, Nina; Berns, Els; Adams, Richard; Zeilinger, Robert; Baron, Udo; Vergote, Ignace; Maughan, Tim; Marme, Frederik; Dickhaus, Thorsten; Sehouli, Jalid; Olek, Sven.

in: EPIGENETICS-US, Jahrgang 8, Nr. 11, 01.11.2013, S. 1226-35.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Türbachova, I, Schwachula, T, Vasconcelos, I, Mustea, A, Baldinger, T, Jones, KA, Bujard, H, Olek, A, Olek, K, Gellhaus, K, Braicu, I, Könsgen, D, Fryer, C, Ravot, E, Hellwag, A, Westerfeld, N, Gruss, OJ, Meissner, M, Hasan, MT, Weber, M, Hoffmüller, U, Zimmermann, S, Loddenkemper, C, Mahner, S, Babel, N, Berns, E, Adams, R, Zeilinger, R, Baron, U, Vergote, I, Maughan, T, Marme, F, Dickhaus, T, Sehouli, J & Olek, S 2013, 'The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns', EPIGENETICS-US, Jg. 8, Nr. 11, S. 1226-35. https://doi.org/10.4161/epi.26334

APA

Türbachova, I., Schwachula, T., Vasconcelos, I., Mustea, A., Baldinger, T., Jones, K. A., Bujard, H., Olek, A., Olek, K., Gellhaus, K., Braicu, I., Könsgen, D., Fryer, C., Ravot, E., Hellwag, A., Westerfeld, N., Gruss, O. J., Meissner, M., Hasan, M. T., ... Olek, S. (2013). The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. EPIGENETICS-US, 8(11), 1226-35. https://doi.org/10.4161/epi.26334

Vancouver

Türbachova I, Schwachula T, Vasconcelos I, Mustea A, Baldinger T, Jones KA et al. The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. EPIGENETICS-US. 2013 Nov 1;8(11):1226-35. https://doi.org/10.4161/epi.26334

Bibtex

@article{409c13779e9544f199e6ae89916bbfd6,
title = "The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns",
abstract = "The adaptive immune system is involved in tumor establishment and aggressiveness. Tumors of the ovaries, an immune-privileged organ, spread via transceolomic routes and rarely to distant organs. This is contrary to tumors of non-immune privileged organs, which often disseminate hematogenously to distant organs. Epigenetics-based immune cell quantification allows direct comparison of the immune status in benign and malignant tissues and in blood. Here, we introduce the {"}cellular ratio of immune tolerance{"} (immunoCRIT) as defined by the ratio of regulatory T cells to total T lymphocytes. The immunoCRIT was analyzed on 273 benign tissue samples of colorectal, bronchial, renal and ovarian origin as well as in 808 samples from primary colorectal, bronchial, mammary and ovarian cancers. ImmunoCRIT is strongly increased in all cancerous tissues and gradually augmented strictly dependent on tumor aggressiveness. In peripheral blood of ovarian cancer patients, immunoCRIT incrementally increases from primary diagnosis to disease recurrence, at which distant metastases frequently occur. We postulate that non-pathological immunoCRIT values observed in peripheral blood of immune privileged ovarian tumor patients are sufficient to prevent hematogenous spread at primary diagnosis. Contrarily, non-immune privileged tumors establish high immunoCRIT in an immunological environment equivalent to the bloodstream and thus spread hematogenously to distant organs. In summary, our data suggest that the immunoCRIT is a powerful marker for tumor aggressiveness and disease dissemination.",
author = "Ivana T{\"u}rbachova and Tim Schwachula and Ines Vasconcelos and Alexander Mustea and Tina Baldinger and Jones, {Katherine A} and Hermann Bujard and Alexander Olek and Klaus Olek and Katharina Gellhaus and Ioana Braicu and Dominique K{\"o}nsgen and Christy Fryer and Elisabetta Ravot and Alexander Hellwag and Nicole Westerfeld and Gruss, {Oliver J} and Markus Meissner and Hasan, {Mazahir T} and Michael Weber and Ulrich Hoffm{\"u}ller and Sven Zimmermann and Christoph Loddenkemper and Sven Mahner and Nina Babel and Els Berns and Richard Adams and Robert Zeilinger and Udo Baron and Ignace Vergote and Tim Maughan and Frederik Marme and Thorsten Dickhaus and Jalid Sehouli and Sven Olek",
year = "2013",
month = nov,
day = "1",
doi = "10.4161/epi.26334",
language = "English",
volume = "8",
pages = "1226--35",
journal = "EPIGENETICS-US",
issn = "1559-2294",
publisher = "LANDES BIOSCIENCE",
number = "11",

}

RIS

TY - JOUR

T1 - The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns

AU - Türbachova, Ivana

AU - Schwachula, Tim

AU - Vasconcelos, Ines

AU - Mustea, Alexander

AU - Baldinger, Tina

AU - Jones, Katherine A

AU - Bujard, Hermann

AU - Olek, Alexander

AU - Olek, Klaus

AU - Gellhaus, Katharina

AU - Braicu, Ioana

AU - Könsgen, Dominique

AU - Fryer, Christy

AU - Ravot, Elisabetta

AU - Hellwag, Alexander

AU - Westerfeld, Nicole

AU - Gruss, Oliver J

AU - Meissner, Markus

AU - Hasan, Mazahir T

AU - Weber, Michael

AU - Hoffmüller, Ulrich

AU - Zimmermann, Sven

AU - Loddenkemper, Christoph

AU - Mahner, Sven

AU - Babel, Nina

AU - Berns, Els

AU - Adams, Richard

AU - Zeilinger, Robert

AU - Baron, Udo

AU - Vergote, Ignace

AU - Maughan, Tim

AU - Marme, Frederik

AU - Dickhaus, Thorsten

AU - Sehouli, Jalid

AU - Olek, Sven

PY - 2013/11/1

Y1 - 2013/11/1

N2 - The adaptive immune system is involved in tumor establishment and aggressiveness. Tumors of the ovaries, an immune-privileged organ, spread via transceolomic routes and rarely to distant organs. This is contrary to tumors of non-immune privileged organs, which often disseminate hematogenously to distant organs. Epigenetics-based immune cell quantification allows direct comparison of the immune status in benign and malignant tissues and in blood. Here, we introduce the "cellular ratio of immune tolerance" (immunoCRIT) as defined by the ratio of regulatory T cells to total T lymphocytes. The immunoCRIT was analyzed on 273 benign tissue samples of colorectal, bronchial, renal and ovarian origin as well as in 808 samples from primary colorectal, bronchial, mammary and ovarian cancers. ImmunoCRIT is strongly increased in all cancerous tissues and gradually augmented strictly dependent on tumor aggressiveness. In peripheral blood of ovarian cancer patients, immunoCRIT incrementally increases from primary diagnosis to disease recurrence, at which distant metastases frequently occur. We postulate that non-pathological immunoCRIT values observed in peripheral blood of immune privileged ovarian tumor patients are sufficient to prevent hematogenous spread at primary diagnosis. Contrarily, non-immune privileged tumors establish high immunoCRIT in an immunological environment equivalent to the bloodstream and thus spread hematogenously to distant organs. In summary, our data suggest that the immunoCRIT is a powerful marker for tumor aggressiveness and disease dissemination.

AB - The adaptive immune system is involved in tumor establishment and aggressiveness. Tumors of the ovaries, an immune-privileged organ, spread via transceolomic routes and rarely to distant organs. This is contrary to tumors of non-immune privileged organs, which often disseminate hematogenously to distant organs. Epigenetics-based immune cell quantification allows direct comparison of the immune status in benign and malignant tissues and in blood. Here, we introduce the "cellular ratio of immune tolerance" (immunoCRIT) as defined by the ratio of regulatory T cells to total T lymphocytes. The immunoCRIT was analyzed on 273 benign tissue samples of colorectal, bronchial, renal and ovarian origin as well as in 808 samples from primary colorectal, bronchial, mammary and ovarian cancers. ImmunoCRIT is strongly increased in all cancerous tissues and gradually augmented strictly dependent on tumor aggressiveness. In peripheral blood of ovarian cancer patients, immunoCRIT incrementally increases from primary diagnosis to disease recurrence, at which distant metastases frequently occur. We postulate that non-pathological immunoCRIT values observed in peripheral blood of immune privileged ovarian tumor patients are sufficient to prevent hematogenous spread at primary diagnosis. Contrarily, non-immune privileged tumors establish high immunoCRIT in an immunological environment equivalent to the bloodstream and thus spread hematogenously to distant organs. In summary, our data suggest that the immunoCRIT is a powerful marker for tumor aggressiveness and disease dissemination.

U2 - 10.4161/epi.26334

DO - 10.4161/epi.26334

M3 - SCORING: Journal article

C2 - 24071829

VL - 8

SP - 1226

EP - 1235

JO - EPIGENETICS-US

JF - EPIGENETICS-US

SN - 1559-2294

IS - 11

ER -